Strategic Partnerships Rheonix previously engaged in collaboration with Eurofins CDMO Alphora to offer Listeria PatternAlert testing, and partnered with the FDA on a Cyclospora cayetanensis project. Potential sales opportunities could focus on reinstating or replicating their platform-enabled diagnostic partnerships with large food safety and regulatory organizations, as well as expanding menu items for pathogen panels.

Automated Platform The company developed fully automated testing solutions around the Encompass platform. A sales angle could target laboratories seeking end-to-end automation, including instrument integration, workflow optimization, and rapid deployment of multiplex assays for food safety, clinical, and environmental testing.

COVID-19 Footprint Rheonix had active COVID-19 PCR testing capabilities and approvals from New York State, with a history of rapid deployment for same-day results with Cayuga Health. Opportunities exist to position modular, automated PCR-based workflows to regional health systems or research labs seeking combat readiness for respiratory pathogen surges or routine diagnostics.

Leadership & Expertise Key hires and board appointments in medical oversight and diagnostics indicate strong clinical and regulatory intent. Leverage these relationships to craft value propositions around clinical validation, regulatory pathway support, and risk management for potential customers evaluating sophisticated molecular panels.

Financial Position Revenue range of 10–25 million and total funding of 87 million suggest a company with market credibility but recent cessation of operations. Sales strategies could emphasize asset recovery, licensing of technology, and partnerships to monetize the Encompass platform through sublicensing, service contracts, or white-label collaborations for ongoing customers and ecosystem partners.